UA103616C2 - Замещенные гамма-лактамы как терапевтические агенты - Google Patents

Замещенные гамма-лактамы как терапевтические агенты

Info

Publication number
UA103616C2
UA103616C2 UAA201013802A UAA201013802A UA103616C2 UA 103616 C2 UA103616 C2 UA 103616C2 UA A201013802 A UAA201013802 A UA A201013802A UA A201013802 A UAA201013802 A UA A201013802A UA 103616 C2 UA103616 C2 UA 103616C2
Authority
UA
Ukraine
Prior art keywords
therapeutic agents
substituted gamma
lactams
gamma lactams
substituted
Prior art date
Application number
UAA201013802A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Девид В. Олд
Денни Т. Динх
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of UA103616C2 publication Critical patent/UA103616C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201013802A 2008-04-24 2009-04-22 Замещенные гамма-лактамы как терапевтические агенты UA103616C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4750108P 2008-04-24 2008-04-24
PCT/US2009/041389 WO2009132088A1 (en) 2008-04-24 2009-04-22 Substituted gamma lactams as therapeutic agents

Publications (1)

Publication Number Publication Date
UA103616C2 true UA103616C2 (ru) 2013-11-11

Family

ID=40852537

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201013802A UA103616C2 (ru) 2008-04-24 2009-04-22 Замещенные гамма-лактамы как терапевтические агенты

Country Status (19)

Country Link
US (1) US7820661B2 (enExample)
EP (1) EP2291368B1 (enExample)
JP (1) JP5524181B2 (enExample)
KR (1) KR20110008263A (enExample)
CN (1) CN102076681A (enExample)
AU (1) AU2009239372B2 (enExample)
BR (1) BRPI0911347A2 (enExample)
CA (1) CA2722529A1 (enExample)
CO (1) CO6321273A2 (enExample)
DK (1) DK2291368T3 (enExample)
ES (1) ES2399314T3 (enExample)
IL (1) IL208899A0 (enExample)
MX (1) MX2010011636A (enExample)
MY (1) MY150518A (enExample)
PL (1) PL2291368T3 (enExample)
RU (1) RU2543379C2 (enExample)
UA (1) UA103616C2 (enExample)
WO (1) WO2009132088A1 (enExample)
ZA (1) ZA201007553B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
ES2332049T5 (es) 2003-08-07 2014-03-27 Allergan, Inc. Composiciones de administración de sustancias terapéuticas en los ojos
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8377984B2 (en) * 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
CA2721749A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
EP2291367A1 (en) * 2008-04-24 2011-03-09 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US8124648B2 (en) * 2008-05-20 2012-02-28 Allergan, Inc. Therapeutic lactams
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
WO2014031581A1 (en) * 2012-08-21 2014-02-27 Allergan, Inc. Process for the synthesis of substituted gamma lactams
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
WO2016054596A1 (en) * 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US395798A (en) * 1889-01-08 reason
US4007210A (en) 1973-04-27 1977-02-08 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenylmethoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanates
US3985798A (en) 1975-01-27 1976-10-12 American Cyanamid Company 11α-HOMO-PROSTANOIC ACIDS AND ESTERS
US4060540A (en) 1975-09-18 1977-11-29 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
ES2052735T3 (es) 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US6034413A (en) * 1997-02-27 2000-03-07 Texas Instruments Incorporated High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
KR20040015364A (ko) * 2001-07-16 2004-02-18 에프. 호프만-라 로슈 아게 Ｅｐ4 수용체 작용물질로서의 프로스타글란딘 유사체
CN1617868A (zh) 2001-11-05 2005-05-18 阿勒根公司 作为EP2－受体激动剂的ω－环烷基17－杂芳基前列腺素E2 类似物
NZ535024A (en) * 2002-03-05 2006-10-27 Ono Pharmaceutical Co 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1556347A4 (en) 2002-06-10 2006-08-09 Applied Research Systems GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE
AU2003275838A1 (en) 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
WO2006069276A2 (en) * 2004-12-22 2006-06-29 Janssen Pharmaceutica N.V. TRICYCLIC ō-OPIOID MODULATORS
BRPI0609021A2 (pt) * 2005-03-10 2010-01-12 Allergan Inc gama lactamas substituìdas, composição e uso das mesmas
US8039507B2 (en) 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
US7592364B2 (en) 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP1996546B1 (en) * 2006-03-20 2014-11-26 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
WO2008021975A2 (en) 2006-08-11 2008-02-21 Allergan, Inc. Therapeutic lactams
US7507817B2 (en) 2006-11-17 2009-03-24 Allergan, Inc. Prostaglandin prodrugs
CA2676291C (en) * 2007-01-31 2017-11-28 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
EP2291367A1 (en) * 2008-04-24 2011-03-09 Allergan, Inc. Substituted gamma lactams as therapeutic agents

Also Published As

Publication number Publication date
IL208899A0 (en) 2011-01-31
JP2011518833A (ja) 2011-06-30
MY150518A (en) 2014-01-30
US7820661B2 (en) 2010-10-26
RU2010144637A (ru) 2012-05-27
US20090270392A1 (en) 2009-10-29
MX2010011636A (es) 2010-11-25
BRPI0911347A2 (pt) 2018-03-20
EP2291368B1 (en) 2012-12-19
CA2722529A1 (en) 2009-10-29
ES2399314T3 (es) 2013-03-27
RU2543379C2 (ru) 2015-02-27
KR20110008263A (ko) 2011-01-26
EP2291368A1 (en) 2011-03-09
AU2009239372B2 (en) 2013-09-19
DK2291368T3 (da) 2013-03-18
JP5524181B2 (ja) 2014-06-18
CO6321273A2 (es) 2011-09-20
ZA201007553B (en) 2011-08-31
WO2009132088A1 (en) 2009-10-29
AU2009239372A1 (en) 2009-10-29
CN102076681A (zh) 2011-05-25
PL2291368T3 (pl) 2013-05-31

Similar Documents

Publication Publication Date Title
UA103616C2 (ru) Замещенные гамма-лактамы как терапевтические агенты
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
GB0920703D0 (en) Compositions containing satiogens and methods of use
MY181898A (en) Heterocyclic compounds and uses thereof
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
EA201170521A1 (ru) Новые соединения
PH12012502569A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
IN2012DN02556A (enExample)
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2012004264A (es) Derivados de sulfoxidos para el tratamiento de tumores.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
MY185134A (en) 6-substituted phenoxychroman carboxylic acis derivatives
PH12012501389A1 (en) Hedgehog inhibitors
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
NZ606730A (en) Methods for treating antipsychotic-induced weight gain
IN2012DN03844A (enExample)